Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $43
Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $43
Wells Fargo保持Apellis Pharmaceuticals的等權重評級，將目標股價下調至43美元
Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and lowers the price target from $47 to $43.
Wells Fargo 分析師 Derek Archila 維持 apellis pharmaceuticals（納斯達克：APLS）的「等權重」評級，並將目標股價從47美元降至43美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。